Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Acquisitions & Divestments (2025)

NewAmsterdam Pharma (NAMS) has disclosed Change in Acquisitions & Divestments for 1 consecutive years, with $50.5 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments changed N/A to $50.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $122.1 million for FY2025, N/A changed from the prior year.
  • Change in Acquisitions & Divestments hit $50.5 million in Q4 2025 for NewAmsterdam Pharma, up from $34.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $50.5 million in Q4 2025 to a low of $12.5 million in Q1 2025.